| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 05/16/2006 | US7045534 Methods of reducing angiogenesis |
| 05/16/2006 | US7045533 Such as naphthalen-1-yl-(4-pentyloxy-naphthalen-1-yl)-mehtane for treatment/prevention of diseases/conditions associated with cannobinoid receptor activation such as chronic pain, osteo- and rheumatoid arthritis, teno-synovitis and gout |
| 05/16/2006 | US7045523 Administering a synergistic mixture of Imatinab and a telomerase inhibitor, e.g., telomestatin, for the delay of progression or treatment of leukemia or Imatinib-resistant leukemia; antiproliferative agents |
| 05/16/2006 | US7045511 Fosinopril formulation |
| 05/16/2006 | US7045507 Substituted tetracycline compounds as synergistic antifungal agents |
| 05/16/2006 | US7045505 Isolation nucleic acids; genetic engineering; diagnosis, therapy, prevention hematopoietic, nervous system disorders |
| 05/16/2006 | US7045501 Method of treating chronic cardiac disease |
| 05/16/2006 | US7045498 Soluble Zcytor11 cytokine receptors |
| 05/16/2006 | US7045345 G-coupled receptor showing selective affinity for ATP |
| 05/16/2006 | US7045323 Glutathione reductase for therapy and prophylaxis of aids |
| 05/16/2006 | US7045315 Methods for modulating expression of exogenous genes in mammalian systems |
| 05/16/2006 | US7045302 Expressed ligand-vascular intercellular signaling molecule |
| 05/16/2006 | US7045290 Prevention protein misfolding; central nervous system disorders; Alzheimer's, Parkinson's, Huntington's disease therapy |
| 05/16/2006 | US7045283 Detecting preferential ligands in cell; obtain cell, incubate with reporter molecules, detect reporter in cell |
| 05/16/2006 | US7045280 Assay method |
| 05/16/2006 | US7045155 Phytooestrogen selected from genistein, daidzein; for promoting health in cases of cancer, pre-menstrual syndrome, menopause or hypercholesterolaemia |
| 05/16/2006 | US7045152 Pulmonary disorders in which the S-nitrosoglutathione(GSNO) pool or glutathione pool in the lung is depleted and where reactive oxygen species in lung are increased, are treated by delivering into the lung an agent causing repletion of GSNO |
| 05/16/2006 | US7045146 Treating the solid particle material with an amphiphilic substance and coating the material with a layer of a charged polyelectrolyte or with a multilayer comprising alternating layers of oppositely charged polyelectrolytes. |
| 05/16/2006 | US7045143 Mixture of lecithin and fatty acid; antiinflammatory agents; diseases of lipid metabolism; immunology disorders |
| 05/16/2006 | US7045127 Human anti-epidermal growth factor receptor single-chain antibodies |
| 05/16/2006 | US7045118 Delivery of compounds for the treatment of migraine through an inhalation route |
| 05/16/2006 | CA2291274C Uses of oil bodies |
| 05/11/2006 | WO2006050489A2 Methods of entrapping, inactivating, and removing viral infections by the administration of respiratory tract compositions |
| 05/11/2006 | WO2006050037A1 Adjunctive therapy for depression |
| 05/11/2006 | WO2006049312A1 Remedy for neuropathic pain |
| 05/11/2006 | WO2006049304A1 Aryloxy-substituted benzimidazole derivatives |
| 05/11/2006 | WO2006049286A1 Preventive/remedy for allergic diseases |
| 05/11/2006 | WO2006049215A1 Combination drug for treating autoimmune disease |
| 05/11/2006 | WO2006048633A2 Combination comprising zd6474 and an antiandrogen |
| 05/11/2006 | WO2006048294A1 Combinations of nicotinic acetylcholine alpha 7 receptor agonists |
| 05/11/2006 | WO2006029018A3 Combinatorial chemotherapy treatment using na+/k+-atpase inhibitors |
| 05/11/2006 | WO2006017563A9 Compositions and methods for reversing age-related changes in extracellular matrix proteins |
| 05/11/2006 | WO2005120407A3 Preparation for localized delivery of therapeutic agent |
| 05/11/2006 | WO2005115076A3 Combi-preparation of a green lipped mussel extract and a non-steroidal anti-inflammatory drug. |
| 05/11/2006 | WO2005107808A3 Combination of atypical antipsychotics and 5-ht1b receptor antagonists |
| 05/11/2006 | WO2005102390A3 Combinations comprising alpha-2-delta ligands and nmda receptor antagonists |
| 05/11/2006 | WO2005102275B1 Galantamine salts, method of producing it and nasal composition thereof |
| 05/11/2006 | WO2005101838A8 Piperazinylpiperidine derivatives as chemokine receptor antagonists |
| 05/11/2006 | WO2005089731A3 Use of renin inhibitors in therapy |
| 05/11/2006 | WO2005033272A3 In vivo synthesis of connective tissues |
| 05/11/2006 | WO2004096151A3 Methods and devices for the sustained release of multiple drugs |
| 05/11/2006 | WO2002055100A9 Method and composition for inhibition of tumor growth and enhancing an immune response |
| 05/11/2006 | US20060101530 Rors as modifiers of the p21 pathway and methods of use |
| 05/11/2006 | US20060100285 N-hydroxy-4-[2-(4-trifluoromethyl-phenyl)-acetylamino]-benzamide for example; treating infammatory, autoimmune diseases, tumors, and neurodegenerative diseases |
| 05/11/2006 | US20060100281 Method of treating tinnitus |
| 05/11/2006 | US20060100276 Method of treating neutrophil-related diseases with topical anesthetics |
| 05/11/2006 | US20060100272 Formulations for the treatment of pain |
| 05/11/2006 | US20060100249 Pharmaceutical compositions comprising dihydropyridinone compounds and an immunoregulatory or an antiinflammatory agent and their uses |
| 05/11/2006 | US20060100247 Treatment of diabetes with thiazolidinedione and metformin |
| 05/11/2006 | US20060100227 Pyrimidine derivaties |
| 05/11/2006 | US20060100205 Compositions for affecting weight loss |
| 05/11/2006 | US20060100178 Dermal agent |
| 05/11/2006 | US20060100167 Methods and compositions for the treatment of autoimmune disorders using clofarabine |
| 05/11/2006 | US20060100159 Preventing desensitization of receptors |
| 05/11/2006 | US20060100152 Methods and compositions in treating pain and painful disorders using 9949, 14230, 760, 62553, 12216, 17719, 41897, 47174, 33408, 10002, 16209, 314, 636, 27410, 33260, 619, 15985, 69112, 2158, 224, 615, 44373, 95431, 22245, 2387, 16658, 55054, 16314, 1613, 1675, 9569 or 13424 molecules |
| 05/11/2006 | US20060100139 Pharmaceutical used for treating HIV infection, the composition and uses thereof |
| 05/11/2006 | US20060100134 fusion proteins; drug delivery |
| 05/11/2006 | US20060099682 Human vanilloid receptors and their uses |
| 05/11/2006 | US20060099640 SLO2 and SLO4, novel potassium channel proteins from human brain |
| 05/11/2006 | US20060099591 Diagnosis of chronic rejection |
| 05/11/2006 | US20060099239 Dietary supplement for promoting removal of heavy metals from the body |
| 05/11/2006 | US20060099237 Antimicrobial medical articles containing a combination of anti-infective compounds, octoxyglycerin, salicylic acid, and sesquiterpenoids |
| 05/11/2006 | US20060099197 identifying a mammalian subject having an infection with said pathogenic Clostridium bacterium resistant to antibiotic, orally administering a therapeutically-effective concentration of Bacillus coagulans bacteria; reducing gastrointestinal colonization by a pathogenic Clostridium bacterium |
| 05/11/2006 | US20060099196 Photoprotective orally administrable composition for skin |
| 05/11/2006 | US20060099185 Drug delivery; sustained, high-level expression of a delivered nucleotide sequence encoding erythropoietin, and for in vivo secretion thereof from transduced muscle cells such that systemic delivery |
| 05/11/2006 | US20060099150 Compositions and methods for the transport of biologically active agents across cellular barriers |
| 05/11/2006 | US20060099141 Radiation sensitive liposomes |
| 05/11/2006 | CA2589808A1 Combination drug for treating autoimmune disease |
| 05/11/2006 | CA2587481A1 Phenylalkylamino carbamates adjunctive therapy for depression |
| 05/11/2006 | CA2586254A1 Therapeutic agent for neuropathic pain |
| 05/11/2006 | CA2586039A1 Methods of entrapping, inactivating, and removing viral infections by the administration of respiratory tract compositions |
| 05/11/2006 | CA2583570A1 Combination comprising zd6474 and an antiandrogen |
| 05/11/2006 | CA2582436A1 Combinations of nicotinic acetylcholine alpha 7 receptor agonists |
| 05/10/2006 | EP1655605A2 Treatment and diagnosis of cancer |
| 05/10/2006 | EP1655382A2 Colon specific gene and protein |
| 05/10/2006 | EP1655280A1 Dicarboxylic acid derivates with pharmaceutical properties |
| 05/10/2006 | EP1655037A1 Serum cholesterol lowering agnet or preventive or therapeutic agent for atherosclerosis |
| 05/10/2006 | EP1655029A1 Medicinal compositions |
| 05/10/2006 | EP1654348A2 Bacterial strains, compositions including same and probiotic use thereof |
| 05/10/2006 | EP1654285A2 Amino acid sequences facilitating penetration of a substance of interest into cells and/or cell nuclei |
| 05/10/2006 | EP1654247A1 Alkynyl aryl carboxamides |
| 05/10/2006 | EP1654001A2 Medicaments for inhalation comprising steroids and a betamimetic |
| 05/10/2006 | EP1653989A2 Anti-bacterial composition, especially for controlling gram-negative bacteria, comprising a peptide and an advantageously hydrophobic anti-bacterial agent |
| 05/10/2006 | EP1653975A1 Compositions and methods for treating, preventing and/or ameliorating cancers, the onset of cancers or the symptoms of cancers |
| 05/10/2006 | EP1653973A1 Combinations comprising staurosporines |
| 05/10/2006 | EP1653970A2 Gsk-3 inhibitors and uses thereof |
| 05/10/2006 | EP1653967A2 Combination of a cox-2 inhibitor and an alkylating-type antineoplastic agent for treatment of neoplasia |
| 05/10/2006 | EP1653966A1 Treatment of sexual dysfunction |
| 05/10/2006 | EP1653958A1 Nicotinamide compounds useful as pde4 inhibitors |
| 05/10/2006 | EP1653956A1 Combinations of paroxetine and 4-(s)-(4-acetyl-piperazin-1-yl)-2-(r)-(4-fluoro-2-methyl-phenyl)-piperidine-1-carboxylic acid ¬1-(r)-(3,5-bis-trifluoromethyl-phenyl)-ethyl|methylamide for treatment of depression and/or anxiety. |
| 05/10/2006 | EP1653953A2 Drug delivery methods and devices |
| 05/10/2006 | EP1653943A2 Compounds and methods for inducing apoptosis in cancer cells |
| 05/10/2006 | EP1653940A1 Therapeutic combination of a cox-2 inhibitor and an aromatase inhibitor |
| 05/10/2006 | EP1653936A2 Solid dispersible and/or orodispersible non-filmy containing at least one type of active substance pharmaceutical composition and method for the preparation thereof |
| 05/10/2006 | EP1653928A2 Spray drying processes for forming solid amorphous dispersions of drugs and polymers |
| 05/10/2006 | EP1653926A1 Dosage forms providing controlled release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors |
| 05/10/2006 | EP1653910A2 Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease |
| 05/10/2006 | EP1509598A4 Induction of insulin expression |
| 05/10/2006 | EP1483374B1 Use of l-alpha-lysophosphatidycholine to obtain the differentiation of monocytes in mature dendritric cells in vitro |
| 05/10/2006 | EP1441742A4 Axon repair |